Research and Markets has announced the addition of the "Esophageal Cancer - Pipeline Review, H2 2016" report to their offering.
Esophageal Cancer pipeline therapeutics constitutes close to 76 molecules. Out of which approximately 69 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Esophageal Cancer - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Esophageal Cancer Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Risk factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.
The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 34, 19, 1, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 2 and 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/c2qnv2/esophageal_cancer
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006405/en/Business Wire
Last updated on: 24/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.